Share on StockTwits

Investment analysts at Credit Suisse initiated coverage on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a note issued to investors on Thursday. The firm set a “neutral” rating on the stock.

Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 2.54% during mid-day trading on Thursday, hitting $165.64. The stock had a trading volume of 930,376 shares. Alexion Pharmaceuticals has a 1-year low of $100.89 and a 1-year high of $185.43. The stock has a 50-day moving average of $164.8 and a 200-day moving average of $162.. The company has a market cap of $32.766 billion and a price-to-earnings ratio of 85.19.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings data on Thursday, July 24th. The company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.07 by $0.05. The company had revenue of $512.50 million for the quarter, compared to the consensus estimate of $509.54 million. During the same quarter in the previous year, the company posted $0.73 earnings per share. The company’s revenue for the quarter was up 38.5% on a year-over-year basis. On average, analysts predict that Alexion Pharmaceuticals will post $5.01 earnings per share for the current fiscal year.

In other Alexion Pharmaceuticals news, CEO Leonard Bell unloaded 5,912 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $169.17, for a total transaction of $1,000,133.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

A number of other firms have also recently commented on ALXN. Analysts at Nomura reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $224.00 price target on the stock, up previously from $222.00. Separately, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $222.00 price target on the stock, up previously from $220.00. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $220.00 price target on the stock, up previously from $210.00. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $183.27.

Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.